相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacodynamics and Pharmacokinetics of Single Doses of Prasugrel 30 mg and Clopidogrel 300 mg in Healthy Chinese and White Volunteers: An Open-Label Trial
David S. Small et al.
CLINICAL THERAPEUTICS (2010)
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
David S. Small et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans
Nagy A. Farid et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Jessica L. Mega et al.
CIRCULATION (2009)
Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing An Open-Label, Single-Sequence, Clinical Trial
David S. Small et al.
DRUGS & AGING (2009)
Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38
Rebecca E. Wrishko et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease
D. S. Small et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects
Ying G. Li et al.
PLATELETS (2009)
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
Nagy A. Farid et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects
Nagy A. Farid et al.
PHARMACOTHERAPY (2008)
Prasugrel achieves greater and faster P2Y(12) receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2008)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
Christopher D. Payne et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
A. Sugidachi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
John T. Brandt et al.
AMERICAN HEART JOURNAL (2007)
Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry
Nagy A. Farid et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2007)
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)
Stephen D. Wiviott et al.
AMERICAN HEART JOURNAL (2006)
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
T Jernberg et al.
EUROPEAN HEART JOURNAL (2006)
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
JLF Rehmel et al.
DRUG METABOLISM AND DISPOSITION (2006)
Biology and pharmacology of the platelet P2Y(12) receptor
Robert F. Storey
CURRENT PHARMACEUTICAL DESIGN (2006)
Clopidogrel and ticlopidine:: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis
P Savi et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2005)
分享论文
